Stockscreener 앱 받기
15.37
0.13%
0.02
전일 마감가:
$15.35
열려 있는:
$15.5
하루 거래량:
136.38K
Relative Volume:
0.69
시가총액:
$334.66M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+7.71%
1개월 성능:
+10.42%
6개월 성능:
+32.50%
1년 성능:
+0.00%
1일 변동 폭
$14.88
$15.50
1주일 범위
$14.25
$16.00
52주 변동 폭
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
명칭
Aardvark Therapeutics Inc
전화
(858) 225-7696
주소
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
AARD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
15.37 | 334.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-23 | 개시 | Oppenheimer | Outperform |
| 2025-12-12 | 개시 | William Blair | Outperform |
| 2025-12-03 | 개시 | Raymond James | Strong Buy |
| 2025-11-07 | 개시 | BTIG Research | Buy |
| 2025-09-29 | 개시 | Stifel | Buy |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 개시 | BofA Securities | Buy |
| 2025-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 개시 | Morgan Stanley | Overweight |
| 2025-03-10 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% Higher – Time to Buy? - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Trading 2.5% HigherTime to Buy? - MarketBeat
Treasury Yields: How Aardvark Therapeutics Inc stock compares to growth peersJuly 2025 Summary & Long-Term Capital Growth Ideas - Bộ Nội Vụ
RSI Check: Can Aardvark Therapeutics Inc stock rebound after recent weaknessMarket Activity Summary & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Aardvark Therapeutics updates investor presentation on hunger therapies - TipRanks
Aardvark Therapeutics, Inc Updates Corporate Presentation - TradingView — Track All Markets
Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com Australia
What risks investors should watch in Aardvark Therapeutics Inc. stockBull Run & Safe Capital Growth Tips - Улправда
Can Aardvark Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Spike Watch & Comprehensive Market Scan Insights - Улправда
Will Aardvark Therapeutics Inc. stock deliver consistent dividendsPortfolio Return Report & AI Powered Buy/Sell Recommendations - Улправда
Fed Watch: How Aardvark Therapeutics Inc. stock trades during market volatility2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Nasdaq Moves: How Aardvark Therapeutics Inc. stock trades during market volatilityQuarterly Portfolio Summary & Technical Buy Zone Confirmation - Улправда
What AI ML Trends Might Elevate Advance Metering Technology Limiteds Stock ProspectsLong-Term Growth Stocks & Free Unstoppable Trading Performance - earlytimes.in
Aug Gainers: Will Aardvark Therapeutics Inc stock deliver consistent dividends2025 Momentum Check & Community Trade Idea Sharing Platform - moha.gov.vn
Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
Critical Contrast: Aardvark Therapeutics (AARD) and The Competition - Defense World
Aardvark Therapeutics (AARD) – Investment Analysts’ Recent Ratings Updates - Defense World
Aardvark Therapeutics initiated with an outperform at Oppenheimer - MSN
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Oppenheimer initiates Aardvark Therapeutics stock with Outperform rating - Investing.com India
Oppenheimer Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark Therapeutics, Inc.(NasdaqGS: AARD) added to NASDAQ Biotechnology Index - marketscreener.com
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Is Aardvark Therapeutics Inc. stock attractive for hedge fundsTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - bolumsonucanavari.com
Will Aardvark Therapeutics Inc. stock maintain dividend yieldJuly 2025 Sector Moves & Smart Money Movement Tracker - DonanımHaber
How resilient is Aardvark Therapeutics Inc. stock in market downturns2025 Market Sentiment & Technical Pattern Based Signals - Улправда
Insider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares - simplywall.st
HC Wainwright Has Negative Outlook for AARD FY2025 Earnings - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares - MarketBeat
Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock - MarketBeat
Insider Stock Purchases: December 13, 2025 - Quiver Quantitative
Analysts’ Top Healthcare Picks: Aardvark Therapeutics, Inc. (AARD), Eli Lilly & Co (LLY) - The Globe and Mail
William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating - Investing.com Canada
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 By Investing.com - Investing.com Nigeria
Insider Buying: Nelson Sun Acquires Additional Shares of Aardvar - GuruFocus
Lee Tien-Li, CEO of Aardvark, buys $101k in AARD stock - Investing.com Australia
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
Aardvark Therapeutics Executives Increase Their Holdings - TradingView — Track All Markets
CFO Sun Buys 3,000 ($43.2K) Of Aardvark Therapeutics Inc [AARD] - TradingView — Track All Markets
William Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst - Sahm
William Blair Initiates Aardvark Therapeutics With Outperform Rating - marketscreener.com
Aardvark Therapeutics Inc (AARD) 재무 분석
Aardvark Therapeutics Inc (AARD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Aardvark Therapeutics Inc 주식 (AARD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
4.73%
0.92%
자본화:
|
볼륨(24시간):